Visceral Leishmaniasis in Renal Transplant Recipients: Successful Treatment with Liposomal Amphotericin B (AmBisome) | Zendy

John Boletis | Zendy; Angelos Pefanis | Zendy; Charalampos Stathakis | Zendy; Helen Helioti | Zendy; Apostolos Kostakis | Zendy; Helen Giamarellou | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Visceral Leishmaniasis in Renal Transplant Recipients: Successful Treatment with Liposomal Amphotericin B (AmBisome)

Author(s) -

John Boletis,

Angelos Pefanis,

Charalampos Stathakis,

Helen Helioti,

Apostolos Kostakis,

Helen Giamarellou

Publication year - 1999

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/514784

Subject(s) - medicine , amphotericin b , visceral leishmaniasis , adverse effect , renal transplant , amphotericin b deoxycholate , transplantation , leishmaniasis , gastroenterology , surgery , pharmacology , antifungal , immunology , dermatology , caspofungin

Visceral leishmaniasis (VL) is a rare disease in renal transplant recipients. Liposomal amphotericin B (AmBisome) is known to be effective against VL. However, previously there has been no experience with administration of such treatment to renal transplant recipients. We report herein four patients with VL complicating renal transplantation who were treated successfully with liposomal amphotericin B (total dose, 23-40 mg/kg). Neither adverse reactions nor clinical relapses of VL were observed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research